Sugi Predict

Sugi Predict / Compounds / SCHEMBL16091799

SCHEMBL16091799

SCHEMBL16091799

CN[C@H](C(=O)N[C@@H](CCCNC(N)=O)C(C)=O)C(C)C

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SIRT5 Q9NXA8 2/20 0.36
▸ KISS1R Q969F8 1/20 0.35
▸ C3AR1 Q16581 1/20 0.34
▸ FURIN P09958 5/20 0.34
▸ SIRT6 Q8N6T7 1/20 0.34
▸ SIRT1 Q96EB6 1/20 0.34
▸ LMNA P02545 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ NPY4R P50391 3/20 0.32
▸ NPY1R P25929 2/20 0.32
▸ NPY2R P49146 2/20 0.32
▸ NPY5R Q15761 2/20 0.32
▸ REN P00797 1/20 0.32
▸ NOD1 Q9Y239 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20375659 1.00 SIRT5 (0.36) SIRT5KISS1RC3AR1FURINSIRT6
SCHEMBL15499691 1.00 SIRT5 (0.36) SIRT5KISS1RC3AR1FURINSIRT6
SCHEMBL21103418 1.00 SIRT5 (0.36) SIRT5KISS1RC3AR1FURINSIRT6
SCHEMBL18661755 1.00 SIRT5 (0.36) SIRT5KISS1RC3AR1FURINSIRT6
SCHEMBL20375788 1.00 SIRT5 (0.36) SIRT5KISS1RC3AR1FURINSIRT6
SCHEMBL23393940 0.93 SIRT5 (0.39) SIRT5C3AR1FURINLMNAPOLB
SCHEMBL25092038 0.89 SIRT5 (0.44) SIRT5KISS1RC3AR1FURINSIRT6
SCHEMBL17993275 0.89 SIRT5 (0.44) SIRT5KISS1RC3AR1FURINSIRT6
SCHEMBL24490420 0.89 C3AR1 (0.34) SIRT5C3AR1FURINSIRT6SIRT1
SCHEMBL20795891 0.89 FURIN (0.36) SIRT5C3AR1FURINSIRT6SIRT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024044549-A1 VHH ANTIBODY CONJUGATES Abdera Therapeutics Inc. (US) 2024-02-29 — — WO disclosed
WO-2024044552-A1 VHH ANTIBODY DOTA CONJUGATES Abdera Therapeutics Inc. (US) 2024-02-29 — — WO disclosed
WO-2024044554-A1 VHH ANTIBODY CONJUGATES WITH HETEROARYL CHELATORS Abdera Therapeutics Inc. (US) 2024-02-29 — — WO disclosed
WO-2024036329-A2 CYTOTOXIC COMPOUNDS AND CONJUGATES THEREOF SEAGEN INC. (US) 2024-02-15 — — WO disclosed
WO-2024020164-A2 GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF FIREFLY BIO, INC. (US) 2024-01-25 — — WO disclosed
EP-4306524-A2 LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS PureTech LYT, Inc. (US) 2024-01-17 — — EP disclosed
WO-2023183628-A9 TARGETED DELIVERY JUDO BIO INC. (US) 2023-11-30 — — WO disclosed
WO-2023225320-A1 EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2023-11-23 — — WO disclosed
WO-2023183628-A2 TARGETED DELIVERY JUDO BIO INC. (US) 2023-09-28 — — WO disclosed
WO-2023173074-A2 IMMUNOSTIMULANT-CYTOTOXIC CONJUGATE COMPOSITION AND METHODS FOR CANCER TREATMENT THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2023-09-14 — — WO disclosed
US-9580511-B2 Site-specific antibody-drug conjugation through glycoengineering GENZYME CORPORATION (US) 2017-02-28 — — US disclosed
WO-2016173682-A1 CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER PIERRE FABRE MEDICAMENT (FR) 2016-11-03 — — WO disclosed
US-20160257709-A1 HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY SUTRO BIOPHARMA, INC. 2016-09-08 — — US disclosed
US-20160136299-A1 GLYCOENGINEERED ANTIBODY DRUG CONJUGATES GENZYME CORPORATION 2016-05-19 — — US disclosed
US-20160060354-A1 SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES GENZYME CORPORATION 2016-03-03 — — US disclosed
WO-2015162293-A1 ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER PIERRE FABRE MEDICAMENT (FR) 2015-10-29 — — WO disclosed
WO-2015162291-A1 IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER PIERRE FABRE MEDICAMENT (FR) 2015-10-29 — — WO disclosed
US-20150079070-A1 HYPERGLYCOSYLATED BINDING POLYPEPTIDES GENZYME CORPORATION (US) 2015-03-19 — — US disclosed
US-20140294867-A1 SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING GENZYME CORPORATION (US) 2014-10-02 — — US disclosed
US-20140271676-A1 FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION GENZYME CORPORATION (US) 2014-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140294867-A1 SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING CD2BP2, SIGLEC7, B3GAT3 SIRT5 4043/4885KISS1R 4219/4885C3AR1 1491/4885
US-20150079070-A1 HYPERGLYCOSYLATED BINDING POLYPEPTIDES UGGT1, B4GALT1, GALNT1 SIRT5 4795/4885KISS1R 2641/4885C3AR1 630/4885
US-20140271676-A1 FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION FCGR3B, FCGRT, FCGR2A SIRT5 4586/4885KISS1R 4740/4885C3AR1 81/4885
US-20160060354-A1 SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES CD2BP2, CD74, ENGASE SIRT5 4463/4885KISS1R 4227/4885C3AR1 940/4885
US-20160257709-A1 HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY CYP17A1, HSD17B7, SHBG SIRT5 3145/4885KISS1R 3614/4885C3AR1 2114/4885
US-20160136299-A1 GLYCOENGINEERED ANTIBODY DRUG CONJUGATES CD2BP2, B3GAT3, SIGLEC7 SIRT5 4249/4885KISS1R 4251/4885C3AR1 1231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback